Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies.

Jegaskanda S, Job ER, Kramski M, Laurie K, Isitman G, de Rose R, Winnall WR, Stratov I, Brooks AG, Reading PC, Kent SJ.

J Immunol. 2013 Feb 15;190(4):1837-48. doi: 10.4049/jimmunol.1201574. Epub 2013 Jan 14.

2.

Induction of H7N9-Cross-Reactive Antibody-Dependent Cellular Cytotoxicity Antibodies by Human Seasonal Influenza A Viruses that are Directed Toward the Nucleoprotein.

Jegaskanda S, Co MDT, Cruz J, Subbarao K, Ennis FA, Terajima M.

J Infect Dis. 2017 Mar 1;215(5):818-823. doi: 10.1093/infdis/jiw629.

PMID:
28011910
3.

Age-associated cross-reactive antibody-dependent cellular cytotoxicity toward 2009 pandemic influenza A virus subtype H1N1.

Jegaskanda S, Laurie KL, Amarasena TH, Winnall WR, Kramski M, De Rose R, Barr IG, Brooks AG, Reading PC, Kent SJ.

J Infect Dis. 2013 Oct 1;208(7):1051-61. doi: 10.1093/infdis/jit294. Epub 2013 Jun 28.

PMID:
23812238
4.

Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity in intravenous immunoglobulin as a potential therapeutic against emerging influenza viruses.

Jegaskanda S, Vandenberg K, Laurie KL, Loh L, Kramski M, Winnall WR, Kedzierska K, Rockman S, Kent SJ.

J Infect Dis. 2014 Dec 1;210(11):1811-22. doi: 10.1093/infdis/jiu334. Epub 2014 Jun 10.

PMID:
24916185
5.

Generation and Protective Ability of Influenza Virus-Specific Antibody-Dependent Cellular Cytotoxicity in Humans Elicited by Vaccination, Natural Infection, and Experimental Challenge.

Jegaskanda S, Luke C, Hickman HD, Sangster MY, Wieland-Alter WF, McBride JM, Yewdell JW, Wright PF, Treanor J, Rosenberger CM, Subbarao K.

J Infect Dis. 2016 Sep 15;214(6):945-52. doi: 10.1093/infdis/jiw262. Epub 2016 Jun 28.

PMID:
27354365
6.

Influenza-specific antibody-dependent cellular cytotoxicity: toward a universal influenza vaccine.

Jegaskanda S, Reading PC, Kent SJ.

J Immunol. 2014 Jul 15;193(2):469-75. doi: 10.4049/jimmunol.1400432. Review.

7.

Preexisting Antibody-Dependent Cellular Cytotoxicity-Activating Antibody Responses Are Stable Longitudinally and Cross-reactive Responses Are Not Boosted by Recent Influenza Exposure.

Valkenburg SA, Zhang Y, Chan KY, Leung K, Wu JT, Poon LL.

J Infect Dis. 2016 Oct 15;214(8):1159-63. doi: 10.1093/infdis/jiw346. Epub 2016 Aug 4.

PMID:
27493238
8.

Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.

Ehrlich HJ, Müller M, Kollaritsch H, Pinl F, Schmitt B, Zeitlinger M, Loew-Baselli A, Kreil TR, Kistner O, Portsmouth D, Fritsch S, Maritsch F, Aichinger G, Pavlova BG, Barrett PN.

Vaccine. 2012 Jun 22;30(30):4543-51. doi: 10.1016/j.vaccine.2012.03.061. Epub 2012 Apr 1.

PMID:
22475864
9.

Identification of dominant antibody-dependent cell-mediated cytotoxicity epitopes on the hemagglutinin antigen of pandemic H1N1 influenza virus.

Srivastava V, Yang Z, Hung IF, Xu J, Zheng B, Zhang MY.

J Virol. 2013 May;87(10):5831-40. doi: 10.1128/JVI.00273-13. Epub 2013 Mar 13.

10.

Standard trivalent influenza virus protein vaccination does not prime antibody-dependent cellular cytotoxicity in macaques.

Jegaskanda S, Amarasena TH, Laurie KL, Tan HX, Butler J, Parsons MS, Alcantara S, Petravic J, Davenport MP, Hurt AC, Reading PC, Kent SJ.

J Virol. 2013 Dec;87(24):13706-18. doi: 10.1128/JVI.01666-13. Epub 2013 Oct 9.

11.

Antibody-dependent cell-mediated cytotoxicity against influenza virus-infected cells.

Hashimoto G, Wright PF, Karzon DT.

J Infect Dis. 1983 Nov;148(5):785-94.

PMID:
6605395
12.

Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells.

Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, Cornelissen L, Bakker A, Cox F, van Deventer E, Guan Y, Cinatl J, ter Meulen J, Lasters I, Carsetti R, Peiris M, de Kruif J, Goudsmit J.

PLoS One. 2008;3(12):e3942. doi: 10.1371/journal.pone.0003942. Epub 2008 Dec 16.

13.

Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.

Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, Liu F, Dong L, DeVos JR, Gargiullo PM, Brammer TL, Cox NJ, Tumpey TM, Katz JM.

N Engl J Med. 2009 Nov 12;361(20):1945-52. doi: 10.1056/NEJMoa0906453. Epub 2009 Sep 10.

14.

Neutralizing antibody but not hemagglutination antibody provides accurate evaluation for protective immune response to H5N1 avian influenza virus in vaccinated rabbits.

Zhu H, Ding X, Chen X, Yao P, Xu F, Xie R, Yang Z, Liang W, Zhang Y, Li Y, Shen J, He P, Guo Z, Su B, Sun S, Zhu Z.

Vaccine. 2011 Jul 26;29(33):5421-3. doi: 10.1016/j.vaccine.2011.05.067. Epub 2011 Jun 7.

PMID:
21645575
15.

Relationship of preexisting influenza hemagglutination inhibition, complement-dependent lytic, and antibody-dependent cellular cytotoxicity antibodies to the development of clinical illness in a prospective study of A(H1N1)pdm09 Influenza in children.

Co MD, Terajima M, Thomas SJ, Jarman RG, Rungrojcharoenkit K, Fernandez S, Yoon IK, Buddhari D, Cruz J, Ennis FA.

Viral Immunol. 2014 Oct;27(8):375-82. doi: 10.1089/vim.2014.0061. Epub 2014 Aug 20.

16.

Influenza viruses and cross-reactivity in healthy adults: humoral and cellular immunity induced by seasonal 2007/2008 influenza vaccination against vaccine antigens and 2009 A(H1N1) pandemic influenza virus.

Iorio AM, Bistoni O, Galdiero M, Lepri E, Camilloni B, Russano AM, Neri M, Basileo M, Spinozzi F.

Vaccine. 2012 Feb 21;30(9):1617-23. doi: 10.1016/j.vaccine.2011.12.107. Epub 2012 Jan 13.

PMID:
22245606
17.

CD4+ T-cell immunity after pandemic influenza vaccination cross-reacts with seasonal antigens and functionally differs from active influenza infection.

Schmidt T, Dirks J, Enders M, Gärtner BC, Uhlmann-Schiffler H, Sester U, Sester M.

Eur J Immunol. 2012 Jul;42(7):1755-66. doi: 10.1002/eji.201242393.

18.

Serological response to influenza A H1N1 vaccine (Pandemrix®) and seasonal influenza vaccine 2009/2010 in renal transplant recipients and in hemodialysis patients.

Ott U, Sauerbrei A, Lange J, Schäfler A, Walther M, Wolf G, Wutzler P, Zell R, Krumbholz A.

Med Microbiol Immunol. 2012 Aug;201(3):297-302. doi: 10.1007/s00430-012-0231-8. Epub 2012 Feb 17.

PMID:
22350187
19.

Anti N1 cross-protecting antibodies against H5N1 detected in H1N1 infected people.

Frobert E, Bouscambert-Duchamp M, Escuret V, Mundweiler S, Barthélémy M, Morfin F, Valette M, Gerdil C, Lina B, Ferraris O.

Curr Microbiol. 2010 Jul;61(1):25-8. doi: 10.1007/s00284-009-9571-z. Epub 2009 Dec 25.

PMID:
20033691
20.

High Antibody-Dependent Cellular Cytotoxicity Antibody Titers to H5N1 and H7N9 Avian Influenza A Viruses in Healthy US Adults and Older Children.

Terajima M, Co MD, Cruz J, Ennis FA.

J Infect Dis. 2015 Oct 1;212(7):1052-60. doi: 10.1093/infdis/jiv181. Epub 2015 Mar 20.

Supplemental Content

Support Center